On Thursday, Shares of Kulicke and Soffa Industries Inc. (NASDAQ:KLIC), lost -5.84% to $9.36.
Kulicke & Soffa Industries, declared its fourth fiscal quarter revenue is predictable to be below the company’s formerly stated outlook due to broad-based industry softness. The Company now anticipates fourth quarter revenue to be in the $100 to $110 million range, contrast to the formerly predictable $135 to $145 million range.
The industry has continued to experience high inventory levels and low equipment utilization rates. The Company believes this softer industry environment is largely driven by reduced demand within consumer and communication segments such as PCs, tablets and smartphones. This lower end market demand is anticipated to limit near-term semiconductor unit growth and decrease the industry’s immediate need for incremental production equipment.
The Company will continue to be vigilant in reviewing its cost structure and has initiated measures to address the current market situation, counting execution of near-term operational improvements. The Company anticipates to continue to return capital to shareholders through its existing repurchase program. Additional details on the progress of these initiatives will be offered during the Company’s fourth fiscal quarter results conference call planned on Nov 17, 2015.
Kulicke and Soffa Industries, Inc. designs, manufactures, and sells capital equipment and expendable tools to assemble semiconductor devices, counting integrated circuits, discrete devices, light-emitting diodes (LED), and power modules. It operates in two segments, Equipment and Expendable Tools.
Shares of PNC Financial Services Group Inc (NYSE:PNC), inclined 0.63% to $90.53, during its last trading session.
The PNC Financial Services Group , declared that it anticipates to issue financial results for the third quarter on Wednesday, Oct. 14, 2015. PNC Chairman, President and Chief Executive Officer William S. Demchak and Chief Financial Officer Robert Q. Reilly will hold a conference call for investors the same day at 11 a.m. (EDT).
The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States. It operates through six segments: Retail Banking, Corporate & Institutional Banking, Asset Administration Group, Residential Mortgage Banking, BlackRock, and Non-Planned Assets Portfolio.
At the end of Thursday’s trade, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), gained 0.41% to $228.79.
Pharming Group NV, declared the projected election of Mr Robin Wright as the Company’s new Chief Financial Officer (CFO) and member of the Administration Board at an Extraordinary General Meeting (“EGM”) of shareholders, to be held on Wednesday 28 October 2015 at 14:00 hrs CET.
Mr Wright will be responsible for the financial administration, accounting and investor relations activities of the Company within the CFO role, which has formerly been undertaken by CEO, Dr De Vries, and will serve as a member of the Board of Administration. Following the election of Mr Wright to the Board, the Board of Administration will comprise of Mr Robin Wright (CFO), Prof Bruno Giannetti (COO) and Dr Sijmen de Vries (CEO and Chairman).
Mr Wright is a British citizen. He has extensive senior level experience as a CFO of public companies in both the pharmaceutical and biotechnology industries. He is a qualified accountant and joins Pharming from Sweden-based Karolinska Development AB (KDEV:SS), where he was CFO and Head of Business Development. Mr Wright was also CFO and Head of Business Development at Orexo AB (ORX:SS) in Sweden. Preceding to this, he worked in private equity and corporate finance advisory roles, counting long periods at Citibank Salomon Smith Barney and Barclays de Zoete Wedd. He has accomplished over 165 global license and M&A transactions in addition to many financing transactions within the pharma/biotech sector. Mr Wright holds a BA degree in chemistry from Oxford University and is a Fellow of the Institute of Chartered Accountants in England and Wales in the UK.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Finally, Dean Foods Co (NYSE:DF), ended its last trade with -0.67% loss, and closed at $16.41.
Dean Foods Company, declared that Executive Vice President and Chief Executive Officer Gregg Tanner and Executive Vice President and Chief Financial Officer Chris Bellairs will take part at the Stifel 2015 Consumer Conference being held Sept. 17 in New York.
Administration will be available to provide a business overview, review recent financial results and discuss future opportunities and will host a live audio webcast of its group meeting on Thursday, Sept. 17, 2015, at 9:10 a.m. Eastern Standard Time.
Dean Foods Company, a food and beverage company, processes and distributes milk, and other dairy and dairy case products in the United States. It manufactures, markets, and distributes dairy case products, counting fluid milk, ice cream, cultured dairy products, creamers, ice cream mix, and other dairy products; and produces and distributes juices, teas, and bottled water.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
